We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes.
- Authors
Ratliff, Joseph C; Palmese, Laura B; Reutenauer, Erin L; Tek, Cenk
- Abstract
A possible mechanism of antipsychotic-induced weight gain is activation of hypothalamic monophosphate-dependent kinase (AMPK) mediated by histamine 1 receptors. Alpha-lipoic acid (ALA), a potent antioxidant, counteracts this effect and may be helpful in reducing weight for patients taking antipsychotics. The objective of this open-label study was to assess the efficacy of ALA (1,200 mg) on twelve non-diabetic schizophrenia patients over ten weeks. Participants lost significant weight during the intervention (-2.2 kg±2.5 kg). ALA was well tolerated and was particularly effective for individuals taking strongly antihistaminic antipsychotics (-2.9 kg±2.6 kg vs. -0.5 kg±1.0 kg).
- Publication
Clinical schizophrenia & related psychoses, 2015, Vol 8, Issue 4, p196
- ISSN
1941-2010
- Publication type
Journal Article
- DOI
10.3371/CSRP.RAPA.030113